Sanofi CEO says M&A targets in oncology are 'very expensive'


PARIS (Reuters) - Sanofi's Chief Executive Olivier Brandicourt on Wednesday told investors that he considered M&A targets in oncology to be "very exensive".

"If you are not starting with a platform ... there are few things to 'synergize' and it becomes very difficult," Brandicourt said.

(Reporting by Matthias Blamont; Editing by Richard Lough)